Abstract
Primary hyperparathyroidism (HPT) occurs in 2% of people over the age of 55. Women are affected two to three times more often then men. Postmenopausal women are at the greatest risk. The advent of the multichannel, routine screening of serum chemistries in the 1970s led to a dramatic increase in the detection of hypercalcemia and the diagnosis of underlying HPT. The recognition of HPT and its evolving clinical presentation has also been influenced by greater attention devoted over the last two decades to the screening for bone disease. Chronic parathyroid hormone excess stimulates bone remodeling and ultimately activates osteoclast-mediated destruction of bone. Medical treatment options are evolving for osteoporosis in HPT. Treatments that may improve bone density in HPT include bisphosphonates, estrogen, selective estrogen receptor modulators, and surgery.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. 1999 A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249–1255.
Silverberg SJ, Brown I, Bilezikian JP. 2002 Age as a criterion for surgery in primary hyperparathyroidism. Am J Med 113:681–684.
Wermers R, Khosla S, Atkinson E, Grant C, Hodgson S, O’Fallon W, Melton D. 1998 Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med 104(2):115–122.
Wermers R, Khosla S, Atkinson E, Grant C, Hodgson S, O’Fallon W, Melton D. 1997 The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965–1992. Ann Int Med 126(6):433–440.
Vestergaard P, Mollerup C, Frokjaer V, Christiansen P, Blichert-Toft M, Mosekilde L. 2000 Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 321(7261):598–602.
Silverberg S, Locker FG, Bilezikian JP. 1996 Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab 81(11):4007–4012.
Bilezikian JP, Potts J, El-Hajjfuleihan G, et al. 2002 Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res 17(suppl 2):N2-N11.
Locker FG, Silverberg SJ, Bilezikian JP. 1997 Optimal dietary calcium intake in primary hyperparathyroidism. Am J Med 102(6):543–550.
Raef H, Ingemansson S, Sobhi S, Sultan A, Ahmed M, Chaudhry M. 2004 The effect of vitamin D status on the severity of bone disease and on the other features of primary hyperparathyroidism in a vitamin D deficient region. J Endocrinol Invest 27(9):807–812.
Grey A, Lucus J, Horne A, Gamble G, Davidson JS, Reid IR. 2005 Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 90(4):2122–2126.
Parker CR, Blackwell PJ, Fairbairn KJ, Hosking DJ. 2002 Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab 87(10):4482–4489.
Chow CC, Chan WB, Li JY, et al. 2003 Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88(2):581–587.
Masiukiewicz US, Mitnick M, Grey AB, Insogna KL. 2000 Estrogen modulates parathyroid hormone-induced interleukin-6 production in vivo and in vitro. Endocrinology 141(7):2526–2531.
Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. 1996 Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism: a randomized controlled trial. Ann Int Med 125(5):360–368.
Orr-Walker BJ, Evans MC, Clearwater JM, Horne A, Grey AB, Reis IR, 2000 Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four year follow-up and comparison with healthy postmenopausal women. Arch Int Med 160(14):2161–2166.
MORE Investigators. 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282(7):637–645.
Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. 2003 Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88(3):1174–1178.
Abdelhadi M, Nordenstrom J. 1998 Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 83(11):3845–3851.
AACE/AAES Task Force on Primary Hyperparathyroidism. 2005. AACE Position Statement on Diagnosis and Management of Primary Hyperparathyroidism. Endocrine Pract 11(1):49–54.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wojtowicz, J., Milas, M. Primary hyperparathyroidism in women. Clinic Rev Bone Miner Metab 3, 143–147 (2005). https://doi.org/10.1385/BMM:3:2:143
Issue Date:
DOI: https://doi.org/10.1385/BMM:3:2:143